NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Bushu Pharma Lauded by Frost & Sullivan for Enabling the Launch of Specialty Drugs in Japan and Asia-Pacific - The Gateway to Asia initiative ensures quality and timely delivery through shorter lead times, temperature and humidity control, and streamlined urgent order processing - Bushu-Pharma.com
Bushu Pharma Lauded by Frost & Sullivan for Enabling the Launch of Specialty Drugs in Japan and Asia-Pacific

 

NewswireTODAY - /newswire/ - San Antonio, TX, United States, 2022/07/27 - The Gateway to Asia initiative ensures quality and timely delivery through shorter lead times, temperature and humidity control, and streamlined urgent order processing - Bushu-Pharma.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the pharmaceutical supply chain contract services industry, Frost & Sullivan recognizes Bushu Pharma with the 2022 Japan Customer Value Leadership Award. Bushu Pharma, the premier CDMO in Japan, offers pharmaceutical manufacturing and supply chain management (SCM) solutions, delivering pharmaceutical drug products, specializing in oral solid dosage and parenteral contract manufacturing, supporting clinical trial drug products, and commercial goods, along with packaging according to current Good Manufacturing Practice (GMP) standards. It has established a flexible operational structure capable of handling all SCM functions from import/export to manufacturing on a 24-hour basis. The company mainly caters to pharmaceutical organizations focusing on emerging rare diseases in Asia, especially those without a Japanese subsidiary or limited resources in Japan.

Bushu Pharma works closely with its partners to help organizations successfully launch their products, even with minimal resources. It recently partnered with Suzuken, a Japan-grown specialty pharmaceutical distribution firm, to maximize support for new product launches by specialty pharmaceutical manufacturers seeking to enter Japan’s market. The partnership establishes a one-stop center for manufacturing operations and general logistics in Soka City, Saitama Prefecture, and uses Suzuken’s drug traceability system named Cubixx, to deliver efficient and high-quality products to patients. Cubixx strictly monitors and controls the temperature of specialty drugs, providing an environment for medical professionals to offer medicines safely and securely without compromising quality and risking the patient.

“Bushu Pharma has made its mark in the Japan pharmaceutical supply chain contract services market with its expertise spanning well over two decades. With a track record of exporting drugs to more than 43 countries, the company holds global GMP certifications,” said Azza Fazar, Best Practices Research Analyst for Frost & Sullivan.

Through setting up and utilizing the Kazo Pharmaceutical Joint Logistics Center’s cold storage area of more than a thousand square meters, Bushu Pharma offers contract manufacturing focused on secondary packaging services, such as inspection and labeling. The company has gained substantial industry and operation know-how through its offerings and track record, making it highly sought-after by potential clients and recognized as a business’s essential differentiator resulting in considerable growth. It develops its account management strategy and proposes improvement initiatives based on client feedback and evaluations to ensure high-standard customer service, which is the core to their business mission and delivery. The company listens to clients through personalized project teams and subject matter experts, establishing trust and long-lasting relationships. Bushu Pharma also enables flexible operations and responds to demands with short lead times through a systemic pharmaceutical supply chain in Asia-Pacific that does not rely on direct imports from Europe, thereby reducing the complexity of supply chain throughout Asia.

“Bushu Pharma launched Gateway to Asia in 2021 as an initiative and a value-added offering for international pharmaceutical companies to import bulk products, into Japan for quality inspection, labeling, packaging, and distribution throughout Japan and Asia-Pacific. It eliminates delivery delays, compromised drug environments, and long lead times,” as noted by Surbhi Gupta, Senior Industry Analyst for Frost & Sullivan.

Customer-centric approaches, revolutionary contract services offerings, and exceptional supply chain strategies underpin Bushu Pharma’s impressive growth momentum and trajectory, earning clients’ trust and loyalty and more market share. The company’s high client satisfaction rate, unsurpassed quality maintenance, and continuous improvement enable customer acquisition through word of mouth and offer immense value to existing and new customers, solidifying its reputation in the market. With its strong overall performance, Bushu Pharma earns Frost & Sullivan’s 2022 Japan Customer Value Leadership Award in the pharmaceutical supply chain contract services industry.

Each year, Frost & Sullivan (frost.com) presents this award to the company that demonstrates excellence in implementing strategies that proactively create value for its customers with a focus on improving the return on the investment that customers make in its services or products. The award recognizes the company’s unique focus on augmenting the value that its customers receive, beyond simply good customer service, leading to improved customer retention and customer base expansion.

About Bushu Pharma

Bushu Pharma (bushu-pharma.com/en/) was established in August 1998 as an independent pharmaceutical contract manufacturer. Bushu Pharma, capitalized at 1 billion yen, carries out pharmaceutical drug product contract manufacturing and packaging of clinical trials and commercial products in accordance with the latest cGMP standards. Through the utilization of know-how and the latest industry information, Bushu Pharma prides itself in being able to offer added-value solutions to customers.

Contact: Hideyuki Tanaka, Deputy General Manager, Marketing Division
P: +81 49 273 6386 - E: hideyuki.tanaka[.]bushu-pharma.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bushu Pharma Lauded by Frost & Sullivan for Enabling the Launch of Specialty Drugs in Japan and Asia-Pacific

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Bushu Pharma | Frost & Sullivan
Contact: Tammy Chan - Frost.com 
877-463-7678 tammy.chan[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen’s Iqirvo® Receives U.S. FDA Accelerated Approval as A First-in-class PPAR Treatment for Primary Biliary Cholangitis
Ipsen Presents Long-term Elafibranor Efficacy and Itch-related Quality of Life Data in Patients with Primary Biliary Cholangitis
HUB Organoids B.V. Awarded Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Transforming Drug Development
Immunology Consultants Laboratory Rebrand Highlights R&D and Service Specializations
Ipsen and Skyhawk Therapeutics Announce RNA Targeting Research Collaboration in Rare Neurological Diseases
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer At AACR 2024
Bruker Showcases High-Performance Solutions at Analytica 2024 for Research and Analysis in Applied, Industrial and Biopharma Laboratories
STEMCELL Technologies Announces FDA De Novo Classification for Its EasySep™ CD138 Positive Selection Kit to Support Cancer Diagnostic Tests
ONO Implements Oracle's CTMS for Global Centralized Management of Clinical Trials
BASF Aroma Ingredients Expands its Isobionics® Portfolio with New Natural Flavors
Bruker Completes Acquisition of Optical Cell Imaging Company Phasefocus
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
SCHOTT Pharma Offers Complete Testing Suite for Container Selection and Drug Submission Preparation
STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company
Ipsen’s Onivyde® Regimen, A Potential New Standard-of-care First-line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Limelon Advertising, Co.





 
  ©2005-2024 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)